A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib (Kyprolis) in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

The phase III study randomized 792 patients with relapsed multiple myeloma to receive carfilzomib, lenalidomide, and dexamethasone or lenalidomide and dexamethasone alone. The primary endpoint of the study was progression-free survival (PFS).

The study was overwhelmingly positive, Stewart notes. Patients receiving carfilzomib experienced an 8.7-month extension in PFS compared with lenalidomide and dexamethasone alone. The median PFS was 26.3 with carfilzomib versus 17.6 months without (HR = 0.69; 95% CI, 0.57-0.83; 

 <.0001). At this point, data on overall survival are immature.

View more from the 2014 ASH Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

ASH Annual Meeting and Exposition

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial